Axonics, Inc. (AXNX)
Market Cap | 3.02B |
Revenue (ttm) | 240.92M |
Net Income (ttm) | -75.53M |
Shares Out | 49.53M |
EPS (ttm) | -1.64 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 102,415 |
Open | 61.50 |
Previous Close | 61.07 |
Day's Range | 60.21 - 63.07 |
52-Week Range | 38.41 - 79.92 |
Beta | 0.43 |
Analysts | Buy |
Price Target | 85.23 (+39.7%) |
Earnings Date | Feb 23, 2023 |
About AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ... [Read more]
Financial Performance
In 2021, Axonics's revenue was $180.29 million, an increase of 61.64% compared to the previous year's $111.54 million. Losses were -$80.07 million, 45.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for AXNX stock is "Buy." The 12-month stock price forecast is $85.23, which is an increase of 39.70% from the latest price.
News

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

Axonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Why Axonics Shares Are Trading Higher Today? - Axonics (NASDAQ:AXNX)
Axonics, Inc. AXNX shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23 revenue gu...

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

3 Hot Stocks Going Into the Holiday Weekend
All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?

Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.

Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

Axonics® to Participate in the Piper Sandler Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

Are Medical Stocks Lagging Axonics (AXNX) This Year?
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.

Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun...

Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Axonics (AXNX) This Earnings Season?
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.

Axonics® to Report Third Quarter 2022 Financial Results on October 31
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.

Axonics Inc. (AXNX) Soars to 52-Week High, Time to Cash Out?
Axonics (AXNX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

Axonics® to Participate in September Investor Conferences
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Stock
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bo...